Most respiratory tract infections are caused by viruses. Bacterial respiratory tract infections are usually treated empirically with antibiotic therapy that targets the most probable causative pathogens.…
Med Lett Drugs Ther. 2023 Apr 17; 65(1674):57-62 doi:10.58347/tml.2023.1674a
Most respiratory tract infections are caused by viruses. Bacterial respiratory tract infections are usually treated empirically with antibiotic therapy that targets the most probable causative pathogens. Recommended antibiotic regimens for outpatient treatment of some common respiratory tract infections are listed in Table 1 for adults and Table 2 for children.
More antibiotics are prescribed for treatment of acute otitis media (AOM) than for any other infection in young children. Children with AOM typically present with otalgia, fever, and bulging and erythema of…
Med Lett Drugs Ther. 2022 Feb 7; 64(1643):22-3
More antibiotics are prescribed for treatment of acute otitis media (AOM) than for any other infection in young children. Children with AOM typically present with otalgia, fever, and bulging and erythema of the tympanic membrane.
The FDA has approved a 6% otic suspension formulation of the fluoroquinolone antibiotic ciprofloxacin ( Otiprio – Otonomy) for single-dose treatment of acute otitis externa (swimmer's ear) caused by…
Med Lett Drugs Ther. 2018 Aug 13; 60(1553):135-6
The FDA has approved a 6% otic suspension formulation of the fluoroquinolone antibiotic ciprofloxacin ( Otiprio – Otonomy) for single-dose treatment of acute otitis externa (swimmer's ear) caused by Pseudomonas aeruginosa or Staphylococcus aureus in patients ≥6 months old. Otiprio was approved earlier for prophylaxis in children with bilateral otitis media with effusion who are undergoing tympanostomy tube placement.
The FDA has approved Otovel (Arbor), a combination of the fluoroquinolone antibiotic ciprofloxacin 0.3% and the corticosteroid fluocinolone acetonide 0.025%, for otic treatment of acute otitis media with…
Med Lett Drugs Ther. 2016 Dec 5; 58(1509):153-5
The FDA has approved Otovel (Arbor), a combination of the fluoroquinolone antibiotic ciprofloxacin 0.3% and the corticosteroid fluocinolone acetonide 0.025%, for otic treatment of acute otitis media with tympanostomy tubes (AOMT) in children ≥6 months old. It is the second fluoroquinolone/corticosteroid combination to be approved for this indication; ciprofloxacin 0.3%/dexamethasone 0.1% (Ciprodex) has been available for many years. In December 2015, a suspension of ciprofloxacin 6% (Otiprio) was approved for otic treatment of bilateral otitis media with effusion in children undergoing tympanostomy tube placement.
The FDA has approved ciprofloxacin 6% otic suspension ( Otiprio – Otonomy) for single-dose prophylaxis in children with bilateral otitis media with effusion who are undergoing tympanostomy tube placement. It…
Med Lett Drugs Ther. 2016 May 23; 58(1495):69-70
The FDA has approved ciprofloxacin 6% otic suspension ( Otiprio – Otonomy) for single-dose prophylaxis in children with bilateral otitis media with effusion who are undergoing tympanostomy tube placement. It is the first drug to be approved for this indication in the US. Otic formulations of the fluoroquinolone antibiotics ofloxacin ( Floxin Otic , and generics) and ciprofloxacin (plus dexamethasone; Ciprodex ) have been available for years for treatment of acute otitis media in children with tympanostomy tubes; an otic suspension containing ciprofloxacin and fluocinolone acetonide (Otovel) has recently been approved for the same indication and will be reviewed in a future issue.
The article in the July 14th issue contained an error in the last sentence of the last paragraph beginning on page 55. The instrument's reading is determined not by the degree of protrusion of the tympanic…
Med Lett Drugs Ther. 2008 Aug 11; 50(1292):64
The article in the July 14th issue contained an error in the last sentence of the last paragraph beginning on page 55. The instrument's reading is determined not by the degree of protrusion of the tympanic membrane, but rather by its mobility.
The heptavalent pneumococcal conjugate vaccine ( Prevnar - Wyeth) previously approved by the FDA for prevention of invasive pneumococcal disease in infants and children ( Medical Letter 2000; 42:25 ) has now…
Med Lett Drugs Ther. 2003 Mar 31; 45(1153):27-8
The heptavalent pneumococcal conjugate vaccine ( Prevnar - Wyeth) previously approved by the FDA for prevention of invasive pneumococcal disease in infants and children ( Medical Letter 2000; 42:25 ) has now also been approved for prevention of otitis media. Infants and young children have higher antibody responses to the heptavalent conjugate vaccine (PCV7) than to the older 23-valent pneumococcal polysaccharide vaccine (PPV23) used in adults and older children (D Murray and C Jackson, Mil Med 2002; 167:671).
Many drugs are available for treatment of children with acute otitis media, but the growing prevalence of resistant pathogens is a concern. Acute middle ear infections, even without effective treatment,…
Med Lett Drugs Ther. 1994 Mar 4; 36(917):19-20
Many drugs are available for treatment of children with acute otitis media, but the growing prevalence of resistant pathogens is a concern. Acute middle ear infections, even without effective treatment, generally last only a few days, but antimicrobial therapy can shorten the duration of symptoms and prevent complications such as mastoiditis and meningitis.